SELLAS Life Sciences Group, Inc. — Director's Dealing 2018

Dec 19, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2018-12-17

Reporting Person: Burns John Thomas (VP, Finance & Corp Controller)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1332.00	2023-06-28	Common Stock (33)		Direct
Stock Option (Right to Buy)	$2328.00	2023-11-26	Common Stock (42)		Direct
Stock Option (Right to Buy)	$1050.00	2025-01-15	Common Stock (25)		Direct
Stock Option (Right to Buy)	$1062.00	2025-06-19	Common Stock (33)		Direct
Stock Option (Right to Buy)	$900.00	2025-12-18	Common Stock (50)		Direct
Stock Option (Right to Buy)	$504.00	2026-02-23	Common Stock (125)		Direct
Stock Option (Right to Buy)	$54.30	2027-01-17	Common Stock (500)		Direct
Stock Option (Right to Buy)	$5.24	2028-03-13	Common Stock (20000)		Direct

Footnotes

F1: Fully vested and immediately exercisable.

F2: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.